Title
|
|
|
|
[]FDG PET monitoring of tumour response to chemotherapy : does []FDG uptake correlate with the viable tumour cell fraction?
| |
Author
|
|
|
|
| |
Abstract
|
|
|
|
Because metabolic changes induced by chemotherapy precede the morphological changes, fluorine-18 fluorodeoxyglucose positron emission tomography ([18F]FDG PET) is thought to predict response to therapy earlier and more accurately than other modalities. To be a reliable predictor of response, changes in tumour [18F]FDG uptake should reflect changes in viable cell fraction, but little is known about the contribution of apoptotic and necrotic cancer cells and inflammatory tissue to the [18F]FDG signal. In a tumour mouse model we investigated the relation between chemotherapy-induced changes in various tumoral components and tumour uptake and size. SCID mice were subcutaneously inoculated in the right thigh with 52106 Daudi cells. When the tumour measured 15-20 mm, Endoxan was given intravenously. At different time points [1-15 days (d1-d15) after the injection of Endoxan], ex vivo autoradiography and histopathology were performed in two mice and [18F]FDG uptake in the tumour and tumour size were correlated with the different cell fractions measured with flow cytometry in five mice. At d1/d3, similar reductions in [18F]FDG uptake and viable tumoral cell fraction were observed and these reductions preceded changes in tumour size. By d8/d10, [18F]FDG uptake had stabilised despite a further reduction in viable tumoral cell fraction. At these time points a major inflammatory response was observed. At d15, an increase in viable tumour cells was again observed and this was accurately predicted by an increase in [18F]FDG uptake, while the tumour volume remained unchanged. In contrast with variations in tumour volume, [18F]FDG is a good marker for chemotherapy response monitoring. However, optimal timing seems crucial since a transient increase in stromal reaction may result in overestimation of the fraction of viable cells. |
| |
Language
|
|
|
|
English
| |
Source (journal)
|
|
|
|
European journal of nuclear medicine and molecular imaging. - Heidelberg, 2002, currens
| |
Publication
|
|
|
|
Heidelberg
:
Springer
,
2003
| |
ISSN
|
|
|
|
1619-7070
[print]
1619-7089
[online]
| |
DOI
|
|
|
|
10.1007/S00259-003-1120-6
| |
Volume/pages
|
|
|
|
30
:5
(2003)
, p. 682-688
| |
ISI
|
|
|
|
000183421600008
| |
Full text (Publisher's DOI)
|
|
|
|
| |
Full text (publisher's version - intranet only)
|
|
|
|
| |
|